mRNA Therapeutics Contract Development & Manufacturing Market Size, Share & Trends Analysis Report By Application (Viral Vaccines, Protein Replacement Therapies), By Indication, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Table of Content

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Market Definitions
                    1.3. Information Procurement
                        1.3.1. Purchased Database
                        1.3.2. GVR’s Internal Database
                        1.3.3. Secondary Sources & Third-Party Perspectives
                        1.3.4. Primary Research
                        1.3.5. Details of Primary Research
                    1.4. Information Analysis
                        1.4.1. Data Analysis Models
                    1.5. Market Formulation & Data Visualization
                        1.5.1. Commodity Flow Analysis
                            1.5.1.1. Approach 1 Commodity flow approach
                            1.5.1.2. Approach 2 Country wise market estimation using bottom up approach
                    1.6. Data Validation & Publishing
                    1.7. Global Market CAGR Calculation
                    1.8. List of Secondary Sources
                    1.9. List of Primary Sources
Chapter 2. Executive Summary
                    2.1. Market Snapshot
                    2.2. Segmental Snapshot
                    2.3. Competitive Insights Snapshot
Chapter 3. Market Variables, Trends, and Scope
                    3.1. Market Lineage
                        3.1.1. Parent Market Analysis
                        3.1.2. Ancillary Market Analysis
                    3.2. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market - Market Dynamics
                        3.2.1. Market Driver Analysis
                            3.2.1.1. High adoption of mRNA in vaccines
                            3.2.1.2. High number of researches in mRNA therapeutics
                            3.2.1.3. Fundings for mRNA researches
                        3.2.2. Market Restraint Analysis
                            3.2.2.1. High cost of research
                            3.2.2.2. Availability of substitute therapy at low cost.
                    3.3. Business Environmental Tools Analysis mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market
                        3.3.1. Porter’s Five Forces Analysis
                        3.3.2. PESTLE Analysis
                    3.4. COVID-19 Impact Analysis
Chapter 4. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Application Estimates & Trend Analysis
                    4.1. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market, By Application Key Takeaways
                    4.2. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Application Movement & Market Share Analysis, 2022 & 2030
                    4.3. Viral Vaccines
                        4.3.1. Viral Vaccines Development Market Estimates And Forecasts, 2020 - 2030 (USD Million)
                    4.4. Protein Replacement Therapies
                        4.4.1. Protein Replacement Therapies Market Estimates And Forecasts, 2020 - 2030 (USD Million)
                    4.5. Cancer Immunotherapies
                        4.5.1. Cancer Immunotherapies Market Estimates And Forecasts, 2020 - 2030 (USD Million)
Chapter 5. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Indication Estimates & Trend Analysis
                    5.1. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market, By Indication Key Takeaways
                    5.2. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Indication Movement & Market Share Analysis, 2022 & 2030
                    5.3. Infectious Diseases
                        5.3.1. Infectious Diseases Market Estimates And Forecasts, 2020 - 2030 (USD Million)
                    5.4. Metabolic & Genetic Diseases
                        5.4.1. Metabolic & Genetic Diseases Market Estimates And Forecasts, 2020 - 2030 (USD Million)
                    5.5. Cardiovascular & Cerebrovascular Diseases
                        5.5.1. Cardiovascular & Cerebrovascular Diseases Market Estimates And Forecasts, 2020 - 2030 (USD Million)
Chapter 6. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market End Use Estimates & Trend Analysis
                    6.1. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market, By End Use Key Takeaways
                    6.2. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market End Use Movement & Market Share Analysis, 2022 & 2030
                    6.3. Biotech Companies
                        6.3.1. Innovative Market Estimates And Forecasts, 2020 - 2030 (USD Million)
                    6.4. Pharmaceutical companies
                        6.4.1. Pharmaceutical companies Market Estimates And Forecasts, 2020 - 2030 (USD Million)
                    6.5. Government & Academic Research Institutes
                        6.5.1. Government & Academic Research Institutes Market Estimates And Forecasts, 2020 - 2030 (USD Million)
Chapter 7. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Regional Analysis
                    7.1. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Regional market share analysis, 2022 & 2030
                    7.2. North America
                        7.2.1. North America Market estimates and forecast, 2020 - 2030
                        7.2.2. U.S.
                            7.2.2.1. U.S. Market estimates and forecast, 2020 - 2030
                        7.2.3. Canada
                            7.2.3.1. Canada Market estimates and forecast, 2020 - 2030
                    7.3. Europe
                        7.3.1. Europe Market estimates and forecast, 2020 - 2030
                        7.3.2. UK
                            7.3.2.1. UK Market estimates and forecast, 2020 - 2030
                        7.3.3. Germany
                            7.3.3.1. Germany Market estimates and forecast, 2020 - 2030
                        7.3.4. France
                            7.3.4.1. France Market estimates and forecast, 2020 - 2030
                        7.3.5. Italy
                            7.3.5.1. Italy Market estimates and forecast, 2020 - 2030
                        7.3.6. Spain
                            7.3.6.1. Spain Market estimates and forecast, 2020 - 2030
                        7.3.7. Denmark
                            7.3.7.1. Denmark Market estimates and forecast, 2020 - 2030
                        7.3.8. Sweden
                            7.3.8.1. Sweden Market estimates and forecast, 2020 - 2030
                        7.3.9. Norway
                            7.3.9.1. Norway Market estimates and forecast, 2020 - 2030
                    7.4. Asia Pacific
                        7.4.1. Asia Pacific Market estimates and forecast, 2020 - 2030
                        7.4.2. Japan
                            7.4.2.1. Japan Market estimates and forecast, 2020 - 2030
                        7.4.3. China
                            7.4.3.1. China Market estimates and forecast, 2020 - 2030
                        7.4.4. India
                            7.4.4.1. India Market estimates and forecast, 2020 - 2030
                        7.4.5. South Korea
                            7.4.5.1. South Korea Market estimates and forecast, 2020 - 2030
                        7.4.6. Australia
                            7.4.6.1. Australia Market estimates and forecast, 2020 - 2030
                        7.4.7. Thailand
                            7.4.7.1. Thailand Market estimates and forecast, 2020 - 2030
                        7.4.8. South Korea
                            7.4.8.1. South Korea Market estimates and forecast, 2020 - 2030
                    7.5. Latin America
                        7.5.1. Latin America Market estimates and forecast, 2020 - 2030
                        7.5.2. Brazil
                            7.5.2.1. Brazil Market estimates and forecast, 2020 - 2030
                        7.5.3. Mexico
                            7.5.3.1. Mexico Market estimates and forecast, 2020 - 2030
                        7.5.4. Argentina
                            7.5.4.1. Argentina Market estimates and forecast, 2020 - 2030
                        7.5.5. Colombia
                            7.5.5.1. Colombia Market estimates and forecast, 2020 - 2030
                        7.5.6. Chile
                            7.5.6.1. Chile Market estimates and forecast, 2020 - 2030
                    7.6. MEA
                        7.6.1. MEA Market estimates and forecast, 2020 - 2030
                        7.6.2. South Africa
                            7.6.2.1. South Africa Market estimates and forecast, 2020 - 2030
                        7.6.3. Saudi Arabia
                            7.6.3.1. Saudi Arabia Market estimates and forecast, 2020 - 2030
                        7.6.4. UAE
                            7.6.4.1. UAE Market estimates and forecast, 2020 - 2030
                        7.6.5. Kuwait
                            7.6.5.1. Kuwait Market estimates and forecast, 2020 - 2030
Chapter 8. Competitive Landscape
                    8.1. Company Categorization
                    8.2. Strategy Mapping
                    8.3. Company Profiles/Listing
                        8.3.1. Danaher (Aldevron)
                            8.3.1.1. Overview
                            8.3.1.2. Financial Performance
                            8.3.1.3. Service Benchmarking
                            8.3.1.4. Strategic Initiatives
                        8.3.2. Recipharm AB
                            8.3.2.1. Overview
                            8.3.2.2. Financial Performance
                            8.3.2.3. Service Benchmarking
                            8.3.2.4. Strategic Initiatives
                        8.3.3. Biomay AG
                            8.3.3.1. Overview
                            8.3.3.2. Financial Performance
                            8.3.3.3. Service Benchmarking
                            8.3.3.4. Strategic Initiatives
                        8.3.4. Samsung Biologics
                            8.3.4.1. Overview
                            8.3.4.2. Financial Performance
                            8.3.4.3. Service Benchmarking
                            8.3.4.4. Strategic Initiatives
                        8.3.5. Lonza
                            8.3.5.1. Overview
                            8.3.5.2. Financial Performance
                            8.3.5.3. Service Benchmarking
                            8.3.5.4. Strategic Initiatives
                        8.3.6. Catalent , Inc.
                            8.3.6.1. Overview
                            8.3.6.2. Financial Performance
                            8.3.6.3. Service Benchmarking
                            8.3.6.4. Strategic Initiatives
                        8.3.7. Bio-Indication Inc,
                            8.3.7.1. Overview
                            8.3.7.2. Financial Performance
                            8.3.7.3. Service Benchmarking
                            8.3.7.4. Strategic Initiatives
                        8.3.8. eTheRNA
                            8.3.8.1. Overview
                            8.3.8.2. Financial Performance
                            8.3.8.3. Service Benchmarking
                            8.3.8.4. Strategic Initiatives
                        8.3.9. Kaneka Eurogentec S.A
                            8.3.9.1. Overview
                            8.3.9.2. Financial Performance
                            8.3.9.3. Service Benchmarking
                            8.3.9.4. Strategic Initiatives
                        8.3.10. TriLink BioTechnologies
                            8.3.10.1. Overview
                            8.3.10.2. Financial Performance
                            8.3.10.3. Service Benchmarking
                            8.3.10.4. Strategic Initiatives
                        8.3.11. ApexBio Technology
                            8.3.11.1. Overview
                            8.3.11.2. Financial Performance
                            8.3.11.3. Service Benchmarking
                            8.3.11.4. Strategic Initiatives
                        8.3.12. BioNTech SE.
                            8.3.12.1. Overview
                            8.3.12.2. Financial Performance
                            8.3.12.3. Service Benchmarking
                            8.3.12.4. Strategic Initiatives
                        8.3.13. Biocina
                            8.3.13.1. Overview
                            8.3.13.2. Financial Performance
                            8.3.13.3. Service Benchmarking
                            8.3.13.4. Strategic Initiatives

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 4 Global mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 5 Global mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 6 Global mRNA therapeutics contract development and manufacturing (CDMO) market, by region, 2020 - 2030 (USD Million)
Table 7 North America mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
Table 8 North America mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 9 North America mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 10 North America mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 11 U.S. mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 12 U.S. mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 13 U.S. mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 14 Canada mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020-2030, (USD million
Table 15 Canada mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 16 Canada mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 17 Europe mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
Table 18 Europe mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 19 Europe mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 20 Europe mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 21 Germany mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 22 Germany mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 23 Germany mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 24 UK mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 25 UK mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 26 UK mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 27 France mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 28 France mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 29 France mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 30 France mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 31 Italy mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 32 Italy mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 33 Spain mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 34 Spain mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 35 Spain mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 36 Denmark mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 37 Denmark mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 38 Denmark mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 39 Sweden mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 40 Sweden mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 41 Sweden mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 42 Norway mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 43 Norway mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 44 Norway mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 45 Asia Pacific mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
Table 46 Asia Pacific mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 47 Asia Pacific mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 48 Asia Pacific mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 49 Japan mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 50 Japan mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 51 Japan mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 52 China mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 53 China mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 54 China mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 55 India mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 56 India mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 57 India mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 58 Australia mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 59 Australia mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 60 Australia mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 61 South Korea mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 62 South Korea mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 63 South Korea mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 64 Thailand mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 65 Thailand mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 66 Thailand mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 67 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
Table 68 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 69 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 70 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 71 Brazil mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 72 Brazil mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 73 Brazil mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 74 Mexico mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 75 Mexico mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 76 Mexico mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 77 Argentina mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 78 Argentina mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 79 Argentina mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 80 Middle East & Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
Table 81 Middle East & Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 82 Middle East & Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 83 Middle East & Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 84 South Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 85 South Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 86 South Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 87 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 88 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 89 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 90 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 91 UAE mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 92 UAE mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 93 UAE mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
Table 94 Kuwait mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
Table 95 Kuwait mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
Table 96 Kuwait mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)

List of Figures

Fig. 1 mRNA therapeutics contract development and manufacturing (CDMO) market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot
Fig. 10 Segment snapshot
Fig. 11 Competitive landscape snapshot
Fig. 12 Parent market outlook
Fig. 13 Related/ancillary market outlook
Fig. 14 mRNA Therapeutics Contract Development and Manufacturing (CDMO) - Industry value chain analysis
Fig. 15 mRNA therapeutics contract development and manufacturing (CDMO) market driver analysis
Fig. 16 mRNA therapeutics contract development and manufacturing (CDMO) market restraint analysis
Fig. 17 mRNA therapeutics contract development and manufacturing (CDMO) market: Porter's analysis
Fig. 18 mRNA therapeutics contract development and manufacturing (CDMO) market: PESTLE analysis
Fig. 19 mRNA therapeutics contract development and manufacturing (CDMO) market: application outlook and key takeaways
Fig. 20 mRNA therapeutics contract development and manufacturing (CDMO) market: application market share analysis, 2022 - 2030
Fig. 21 Global viral vaccines development market, 2020 - 2030 (USD Million)
Fig. 22 Global protein replacement therapies market, 2020 - 2030 (USD Million)
Fig. 23 Global cancer immunotherapies market, 2020 - 2030 (USD Million)
Fig. 24 mRNA therapeutics contract development and manufacturing (CDMO) market: Indication outlook and key takeaways
Fig. 25 mRNA therapeutics contract development and manufacturing (CDMO) market: Indication market share analysis, 2022 - 2030
Fig. 26 Global infectious diseases market, 2020 - 2030 (USD Million)
Fig. 27 Global metabolic & genetic diseases market, 2020 - 2030 (USD Million)
Fig. 28 Global cardiovascular and cerebrovascular diseases market, 2020 - 2030 (USD Million)
Fig. 29 mRNA therapeutics contract development and manufacturing (CDMO) market: End-user outlook and key takeaways
Fig. 30 mRNA therapeutics contract development and manufacturing (CDMO) market: End-user market share analysis, 2022 - 2030
Fig. 31 Global biotech companies market, 2020 - 2030 (USD Million)
Fig. 32 Global pharmaceutical companies market, 2020 - 2030 (USD Million)
Fig. 33 Global government & academic research institutes market, 2020 - 2030 (USD Million)
Fig. 34 Regional marketplace: Key takeaways
Fig. 35 Regional marketplace: Key takeaways
Fig. 36 North America mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 37 U.S. key country dynamics
Fig. 38 U.S. mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 39 Canada key country dynamics
Fig. 40 Canada mRNA therapeutics contract development and manufacturing (CDMO) market, 2020 - 2030 (USD Million)
Fig. 41 Europe mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 42 Germany key country dynamics
Fig. 43 Germany mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 44 UK key country dynamics
Fig. 45 UK mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 46 France key country dynamics
Fig. 47 France mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 48 Italy key country dynamics
Fig. 49 Italy mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 50 Spain key country dynamics
Fig. 51 Spain mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 52 Denmark key country dynamics
Fig. 53 Denmark mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 54 Sweden key country dynamics
Fig. 55 Sweden mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 56 Norway key country dynamics
Fig. 57 Norway mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 58 Asia-Pacific mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 59 Japan key country dynamics
Fig. 60 Japan mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 61 China key country dynamics
Fig. 62 China mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 63 India key country dynamics
Fig. 64 India mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 65 Australia key country dynamics
Fig. 66 Australia mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 67 Thailand key country dynamics
Fig. 68 Thailand mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 69 South Korea key country dynamics
Fig. 70 South Korea mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 71 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 72 Brazil key country dynamics
Fig. 73 Brazil mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 74 Mexico key country dynamics
Fig. 75 Mexico mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 76 Argentina key country dynamics
Fig. 77 Argentina mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 78 MEA mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 79 South Africa key country dynamics
Fig. 80 South Africa mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 81 Saudi Arabia key country dynamics
Fig. 82 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 83 UAE key country dynamics
Fig. 84 UAE mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 85 Kuwait key country dynamics
Fig. 86 Kuwait mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 87 Key company categorization
Fig. 88 Company market positioning
Fig. 89 Market participant categorization
Fig. 90 Strategy framework